Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

Classificação em ações #4599
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Preço da ação
$71.43
Valor de mercado
$3.34B
Variação (1 dia)
2.78%
Variação (1 ano)
0.34%
País
US
Negociar Tarsus Pharmaceuticals, Inc. (TARS)

Categoria

Healthcare
Histórico de rendimento de dividendos para Tarsus Pharmaceuticals, Inc. (TARS)
O rendimento de dividendos (TTM) da Tarsus Pharmaceuticals, Inc. (símbolo da ação: TARS) em 2023-12-31 é: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Tarsus Pharmaceuticals, Inc. (TARS) de 2018 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL